Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,416.00+0.10%ETH$2,442.29+0.95%GOLD$4,397.70-0.05%OIL$100.86-1.03%
Smart Investors Daily
MU

NASDAQ · MURA

Mural Oncology plc

Healthcare · Biotechnology

$2.04

Up+$0.00 (+0.00%)

Updated Sep 18, 2026, 1:00 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
35.38M
P/E ratio
-0.24
Dividend yield
0.00%
52-week range
— – —
Volume
127.78K
Avg. volume
170.82K

Price performance

MURA price history

1M range · 0 trading sessions · Daily adjusted prices

MURA does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest MURA news

The latest Smart Investors Daily articles mentioning MURA.

Stock researchCompany · Overview

MURA research

Overview

Company profile and research snapshot.

Company profile

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
MURA recent ratings
DateFirmRatingTarget
Mar 26, 2025HC Wainwright & Co.Buy—
Mar 25, 2025Jones TradingHold—
Mar 12, 2025HC Wainwright & Co.Buy—
Jan 27, 2025Jones TradingBuy—
Nov 14, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

globenewswire.com · Dec 5, 2025

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology plc (“Mural”) (Nasdaq: MURA) (the “Acquisition”) pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the “Scheme”). Mural shareholders received $2.035 in cash per share (the “Consideration”).

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By